Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), announced today that Capricor CEO, Linda Marbán, Ph.D., will provide an update on recent findings after a preliminary review of the Company’s ongoing open-label extension study of the Phase II HOPE-2 trial with lead asset, CAP-1002, at the Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference.
June 17, 2021
· 4 min read